Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health

Bladder Cancer Clinical Trial

Official title:

Feasibility Study: Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00776178
• Other study ID #: 999909007
• Secondary ID: 09-C-N007
• Status: Completed
• Start date: October 17, 2008
• Est. completion date: March 31, 2020

Study information

• Verified date: April 2020
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

• Bladder cancer often recurs after treatment and patient survival varies greatly.

• More knowledge is needed about factors that can help identify patients who are at greater risk of disease recurrence and progression to minimize the need for screening and to help guide treatment.

• The New England Study of Environment and Health (NESEH), conducted by the departments of health in Maine, New Hampshire and Vermont, the Dartmouth Medical School and the NIH, examined the relationship between health and environmental factors such as smoking, diet and water quality in New England. This study provides an opportunity to learn more about patients with bladder cancer.

• Before launching a full-scale follow-up study on bladder cancer, it is necessary to determine the feasibility of obtaining needed follow-up information from patients enrolled in the NESEH.

Objectives:

-To determine the completeness and quality of information about treatment, recurrence, and progression that can be obtained for patients from their medical records.

Eligibility:

-Participants from the NESEH study who are residents of Maine and who were diagnosed with bladder cancer between 2001 and 2003.

Design:

• Determine the vital status of NESEH bladder cancer patients.

• Select a sample of 40 living and 18 deceased patients.

• Interview patients or their next of kin by telephone for about 30 to 45 minutes to update exposure information, obtain names and addresses of all hospitals and physicians they have seen since diagnosis, and obtain authorization to access medical records.

• Obtain and abstract medical records.

Description:

Background:

• Bladder cancer is a highly recurrent disease with substantial variability in survival.

• Patients currently undergo repeated cystoscopy for many years after diagnosis.

• There is a need to identify prognostic markers of recurrence and progression to minimize the need for routine screening and to identify patients who should be treated more aggressively.

• The New England Study of Environment and Health (NESEH), a population-based case control study of 1,213 patients in Maine (ME), Vermont (VT), and New Hampshire (NH), provides an excellent opportunity study the clinical, host-genetic, and environmental determinants of prognosis.

• Before launching a full-scale follow-up study, we need to determine the feasibility of following a population-based case series and of obtaining patient-related (vital status, exposures) and tumor-related (recurrence, progression, pathology) information.

Objectives:

To determine:

• The completeness and quality of information that can be obtained for each patient. The most important issue is the extent to which medical records from private physicians will be needed, and whether private physicians are cooperative.

• Our ability to identify next-of-kin (NOK) of deceased patients.

• The proportion of patients (and NOK) that we can contact and enroll.

• The ability of NOK to provide information on exposures.

Eligibility:

-Bladder cancer patients from ME who participated in the original case-control study (ages 30-79, newly diagnosed with histologically-confirmed carcinoma of the bladder, including carcinoma in situ), excluding those diagnosed after 2003 (5 years of follow-up are needed).

Design:

• Conduct interviews with 40 living patients and the NOK of 9 deceased patients to update exposure information and find out where the patient received health care, the types of treatment received, and whether and when the disease recurred or progressed.

• For living patients or NOK that we are unable to locate (an estimated 10 living patients and 9 NOK), request medical records from health care providers (to see if physicians will provide records in the absence of an authorization form).

• Evaluate participant and physician response rates and the completeness of the medical history information obtained.

• We will proceed with the full study if we obtain sufficient medical information for 70% of the living patients.

• We will examine whether there were important issues related to deceased patients (e.g., NOK identification/enrollment, exposure assessment, access to medical records). If so, consider a simpler approach for this segment of the population (e.g., survival study based on NDI Plus and information available from the NESEH).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 68
• Est. completion date: March 31, 2020
• Est. primary completion date: March 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 79 Years

Eligibility

• INCLUSION CRITERIA:

With the exceptions noted below, all bladder cancer patients who participated in the NESEH and were residents of ME when first diagnosed with bladder cancer will be eligible for this feasibility study. Patients were eligible for the NESEH if they met the following criteria:

• 30-79 years old at initial diagnosis

• Newly diagnosed with histologically-confirmed carcinoma of the urinary bladder (including carcinoma in situ) between September 1, 2001 and October 31, 2004

EXCLUSION CRITERIA:

We will exclude from the feasibility study the following NESEH case participants:

• 44 bladder cancer patients (7 percent) first diagnosed at one of seven hospitals located in remote areas of ME (Aroostook Medical Center, Calais Regional Hospital, Cary Medical Center, Down East Community Hospital, Houlton Regional Hospital, Northern Maine Medical Center, and Mount Desert Hospital); this is for cost considerations;

• Patients diagnosed fewer than 5 years before the feasibility study begins (i.e., after 2003)

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Locations

Country	Name	City	State
United States	National Cancer Institute (NCI), 9000 Rockville Pike	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol. 1997;15(2):84-8. Review. — View Citation

Holmäng S, Hedelin H, Anderström C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995 Jun;153(6):1823-6; discussion 1826-7. — View Citation

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. Epub 2006 Jan 17. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	There is no intervention. We are looking at survival.	Overall Survival	September 30, 2015